STOCK TITAN

[SCHEDULE 13G/A] Structure Therapeutics Inc. American SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

Janus Henderson Group plc filed Amendment No. 3 to a Schedule 13G reporting ownership in Structure Therapeutics Inc. The filing lists 4,573,006 American Depositary Shares, representing 8.0% of the class, with shared voting and dispositive power. A subsidiary disclosure shows JHIUS may be deemed beneficial owner of 4,449,167 shares (7.7%) with shared voting and dispositive power. The report cites the event date 06/30/2025 and is signed on 08/14/2025 by Kristin Mariani. The filer certifies the position is held in the ordinary course and not to influence control. A power of attorney executed on 12/09/2022 is attached.

Janus Henderson Group plc ha presentato l'Emendamento n. 3 al Schedule 13G in cui dichiara la partecipazione in Structure Therapeutics Inc.. La segnalazione indica 4.573.006 American Depositary Shares, pari all'8,0% della classe, con poteri di voto e dispositivi condivisi. Una comunicazione relativa a una controllata mostra che JHIUS può essere considerata beneficiaria di 4.449.167 azioni (7,7%) con poteri di voto e dispositivi condivisi. Il rapporto riporta la data dell'evento 06/30/2025 ed è firmato il 08/14/2025 da Kristin Mariani. Il dichiarante certifica che la posizione è detenuta nell'ordinario esercizio e non per influenzare il controllo. È allegata una procura datata 12/09/2022.

Janus Henderson Group plc presentó la Enmienda nº 3 al Schedule 13G informando su participación en Structure Therapeutics Inc.. El informe detalla 4.573.006 American Depositary Shares, que representan el 8,0% de la clase, con poderes de voto y disposición compartidos. Una divulgación sobre una subsidiaria indica que JHIUS puede considerarse beneficiario de 4.449.167 acciones (7,7%) con los mismos poderes compartidos. El reporte cita la fecha del evento 06/30/2025 y está firmado el 08/14/2025 por Kristin Mariani. El declarante certifica que la posición se mantiene en el curso ordinario y no para influir en el control. Se adjunta un poder fechado el 12/09/2022.

Janus Henderson Group plc는 Schedule 13G에 대한 수정서(No. 3)를 제출하여 Structure Therapeutics Inc.에 대한 보유를 보고했습니다. 제출서에는 4,573,006 American Depositary Shares가 기재되어 있으며, 이는 해당 종류의 8.0%에 해당하고 의결권 및 처분권이 공동으로 부여되어 있다고 밝혔습니다. 자회사 공시에 따르면 JHIUS는 4,449,167주(7.7%)의 실질적 소유자로 간주될 수 있으며, 마찬가지로 의결권 및 처분권이 공동입니다. 보고서는 사건일을 06/30/2025로 적시하고, 08/14/2025에 Kristin Mariani가 서명했습니다. 제출자는 해당 지분이 통상적 거래 과정에서 보유된 것이며 지배권 행사 목적이 아님을 확인했습니다. 12/09/2022에 실행된 위임장이 첨부되어 있습니다.

Janus Henderson Group plc a déposé l'Amendement n°3 au Schedule 13G déclarant sa participation dans Structure Therapeutics Inc.. Le dossier indique 4 573 006 American Depositary Shares, représentant 8,0 % de la catégorie, avec pouvoirs de vote et d'aliénation partagés. Une divulgation au titre d'une filiale montre que JHIUS peut être réputé bénéficiaire de 4 449 167 actions (7,7 %) avec les mêmes pouvoirs partagés. Le rapport mentionne la date de l'événement 06/30/2025 et est signé le 08/14/2025 par Kristin Mariani. Le déclarant certifie que la position est détenue dans le cours normal des affaires et non dans le but d'influencer le contrôle. Une procuration datée du 12/09/2022 est jointe.

Janus Henderson Group plc hat Nachtrag Nr. 3 zum Schedule 13G eingereicht und seine Beteiligung an Structure Therapeutics Inc. gemeldet. Die Einreichung führt 4.573.006 American Depositary Shares auf, was 8,0% der Aktienklasse entspricht, mit gemeinsamem Stimm- und Verfügungsrecht. Eine Tochtergesellschaftsangabe weist aus, dass JHIUS als wirtschaftlicher Eigentümer von 4.449.167 Aktien (7,7%) angesehen werden könnte, ebenfalls mit gemeinsamen Stimm- und Verfügungsrechten. Der Bericht nennt als Ereignisdatum den 06/30/2025 und ist am 08/14/2025 von Kristin Mariani unterschrieben. Der Melder bestätigt, dass die Position im ordentlichen Geschäftsverkehr gehalten wird und nicht dazu dient, die Kontrolle zu beeinflussen. Eine Vollmacht vom 12/09/2022 ist beigefügt.

Positive
  • Material disclosure: Janus Henderson reports 4,573,006 ADS (8.0%), exceeding the 5% reporting threshold
  • Transparency: Filing includes certification that shares are held in the ordinary course and not to influence control
  • Documentation: Power of attorney and signature by the Head of North America Compliance are included
Negative
  • Figure discrepancy: The filing shows 4,573,006 ADS (8.0%) aggregate while also reporting 4,449,167 shares (7.7%) for JHIUS, which may cause confusion without further detail
  • No sole voting power: The filer reports 0 shares of sole voting power, indicating no direct controlling stake

Insights

TL;DR: Janus Henderson reports a material passive stake—4,573,006 ADS (8.0%)—in Structure Therapeutics, disclosed via Schedule 13G Amendment No.3.

The filing explicitly reports an aggregate beneficial position of 4,573,006 ADS (8.0%) with shared voting and dispositive power, indicating a sizable institutional holding above the 5% reporting threshold. The filing is submitted under Rule 13d-1(b) and includes the certification that the securities are held in the ordinary course and not to influence control. The Schedule also identifies a related subsidiary position of 4,449,167 shares (7.7%), and provides a power of attorney for filing authority.

TL;DR: Disclosure shows a significant passive position but contains differing subsidiary and aggregate share figures that merit careful reading.

The document classifies the stake as passive per Schedule 13G and includes the required certification. It reports shared voting/dispositive power rather than sole control, and attaches a power of attorney dated December 9, 2022. Notably, the filing presents two similar but different figures—4,573,006 ADS (8.0%) aggregate and 4,449,167 shares (7.7%) for JHIUS—which are both stated in the filing and should be interpreted as distinct disclosures included by the reporting group.

Janus Henderson Group plc ha presentato l'Emendamento n. 3 al Schedule 13G in cui dichiara la partecipazione in Structure Therapeutics Inc.. La segnalazione indica 4.573.006 American Depositary Shares, pari all'8,0% della classe, con poteri di voto e dispositivi condivisi. Una comunicazione relativa a una controllata mostra che JHIUS può essere considerata beneficiaria di 4.449.167 azioni (7,7%) con poteri di voto e dispositivi condivisi. Il rapporto riporta la data dell'evento 06/30/2025 ed è firmato il 08/14/2025 da Kristin Mariani. Il dichiarante certifica che la posizione è detenuta nell'ordinario esercizio e non per influenzare il controllo. È allegata una procura datata 12/09/2022.

Janus Henderson Group plc presentó la Enmienda nº 3 al Schedule 13G informando su participación en Structure Therapeutics Inc.. El informe detalla 4.573.006 American Depositary Shares, que representan el 8,0% de la clase, con poderes de voto y disposición compartidos. Una divulgación sobre una subsidiaria indica que JHIUS puede considerarse beneficiario de 4.449.167 acciones (7,7%) con los mismos poderes compartidos. El reporte cita la fecha del evento 06/30/2025 y está firmado el 08/14/2025 por Kristin Mariani. El declarante certifica que la posición se mantiene en el curso ordinario y no para influir en el control. Se adjunta un poder fechado el 12/09/2022.

Janus Henderson Group plc는 Schedule 13G에 대한 수정서(No. 3)를 제출하여 Structure Therapeutics Inc.에 대한 보유를 보고했습니다. 제출서에는 4,573,006 American Depositary Shares가 기재되어 있으며, 이는 해당 종류의 8.0%에 해당하고 의결권 및 처분권이 공동으로 부여되어 있다고 밝혔습니다. 자회사 공시에 따르면 JHIUS는 4,449,167주(7.7%)의 실질적 소유자로 간주될 수 있으며, 마찬가지로 의결권 및 처분권이 공동입니다. 보고서는 사건일을 06/30/2025로 적시하고, 08/14/2025에 Kristin Mariani가 서명했습니다. 제출자는 해당 지분이 통상적 거래 과정에서 보유된 것이며 지배권 행사 목적이 아님을 확인했습니다. 12/09/2022에 실행된 위임장이 첨부되어 있습니다.

Janus Henderson Group plc a déposé l'Amendement n°3 au Schedule 13G déclarant sa participation dans Structure Therapeutics Inc.. Le dossier indique 4 573 006 American Depositary Shares, représentant 8,0 % de la catégorie, avec pouvoirs de vote et d'aliénation partagés. Une divulgation au titre d'une filiale montre que JHIUS peut être réputé bénéficiaire de 4 449 167 actions (7,7 %) avec les mêmes pouvoirs partagés. Le rapport mentionne la date de l'événement 06/30/2025 et est signé le 08/14/2025 par Kristin Mariani. Le déclarant certifie que la position est détenue dans le cours normal des affaires et non dans le but d'influencer le contrôle. Une procuration datée du 12/09/2022 est jointe.

Janus Henderson Group plc hat Nachtrag Nr. 3 zum Schedule 13G eingereicht und seine Beteiligung an Structure Therapeutics Inc. gemeldet. Die Einreichung führt 4.573.006 American Depositary Shares auf, was 8,0% der Aktienklasse entspricht, mit gemeinsamem Stimm- und Verfügungsrecht. Eine Tochtergesellschaftsangabe weist aus, dass JHIUS als wirtschaftlicher Eigentümer von 4.449.167 Aktien (7,7%) angesehen werden könnte, ebenfalls mit gemeinsamen Stimm- und Verfügungsrechten. Der Bericht nennt als Ereignisdatum den 06/30/2025 und ist am 08/14/2025 von Kristin Mariani unterschrieben. Der Melder bestätigt, dass die Position im ordentlichen Geschäftsverkehr gehalten wird und nicht dazu dient, die Kontrolle zu beeinflussen. Eine Vollmacht vom 12/09/2022 ist beigefügt.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



JANUS HENDERSON GROUP PLC
Signature:Kristin Mariani
Name/Title:Head of North America Compliance, CCO
Date:08/14/2025
Exhibit Information

POWER OF ATTORNEY The undersigned, Janus Henderson Group plc ("the Company"), does hereby make, constitute and appoint each of Kristin Mariani and Caroline Barotti acting severally, as its true and lawful attorneys in-fact, for the purpose of, from time to time, executing in its name and on its behalf, whether the Company individually or as representative of others, any and all documents, certificates, instruments, statements, other filings and amendments to the foregoing (collectively, "documents") determined by such person to be necessary or appropriate to comply with ownership or control-person reporting requirements imposed by any United States or non-United States governmental or regulatory authority, including, without limitation, Forms 13D, 13F, 13G and 13H and any amendments to any of the foregoing as may be required to be filed with the Securities and Exchange Commission, and delivering, furnishing or filing any such documents with the appropriate governmental, regulatory authority or other person, and giving and granting to each such attorney-in-fact power and authority to act in the premises as fully and to all intents and purposes as the Company might or could do if personally present by one of its authorized signatories, hereby ratifying and confirming all that said attorney-in-fact shall lawfully do or cause to be done by virtue hereof. Any such determination by an attorney-in-fact named herein shall be conclusively evidenced by such person's execution, delivery, furnishing or filing of the applicable document. This power of attorney shall be valid from the date hereof and shall remain in full force and effect until either revoked in writing by the Company, or, in respect of any attorney-in-fact named herein, until such person ceases to be an employee of the Company or one of its affiliates. IN WITNESS WHEREOF, the undersigned has caused this power of attorney to be executed as of this 9th day of December, 2022. Janus Henderson Group plc By: /s/ Michelle Rosenberg Name: Michelle Rosenberg Title: General Counsel and Company Secretary

FAQ

How many Structure Therapeutics (GPCR) shares does Janus Henderson own?

The filing reports an aggregate beneficial position of 4,573,006 ADS (8.0%). A related subsidiary (JHIUS) is reported as beneficial owner of 4,449,167 shares (7.7%).

What type of SEC filing did Janus Henderson submit for GPCR?

Janus Henderson filed an Amendment No. 3 to Schedule 13G under Rule 13d-1(b).

When is the event date and when was the Schedule 13G signed?

The date of the event requiring the filing is 06/30/2025, and the filing is signed on 08/14/2025.

Does the filing indicate intent to influence control of Structure Therapeutics (GPCR)?

The filer certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

Who signed the Schedule 13G for Janus Henderson?

The filing is signed by Kristin Mariani, Head of North America Compliance, CCO.

Is there a power of attorney attached to the filing?

Yes. A power of attorney dated 12/09/2022 names Kristin Mariani and Caroline Barotti to execute ownership reporting filings.
Structure Therapeutics Inc ADR

NASDAQ:GPCR

GPCR Rankings

GPCR Latest News

GPCR Latest SEC Filings

GPCR Stock Data

1.08B
54.76M
3.08%
102.38%
13.65%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO